C30H31N5O4
Neat
525.61
334951-61-0; NINTEDANIB IMPURITY I; (Z)-Methyl 3-(((4-(N-methyl-2-(piperazin-1-yl)acetamido)phenyl)amino)(phenyl)methylene)-2-oxoindoline-6-carboxylate; (Z)-Methyl 3-(((4-(N-methyl-2-(piperazin-1-yl)acetamido)phenyl)amino)(phenyl)methylene)-2-oxoindoline-6-carboxylate ( Nintedanib Impurity); UNII-3TK2E45UHG; 3TK2E45UHG; BIBF1053; Nintedanib metabolite M3 (m/Z 526); methyl 2-hydroxy-3-[N-[4-[methyl-(2-piperazin-1-ylacetyl)amino]phenyl]-C-phenylcarbonimidoyl]-1H-indole-6-carboxylate; 1H-Indole-6-carboxylic acid, 2, 3-dihydro-3-(((4-(methyl(2-(1-piperazinyl)acetyl)amino)phenyl)amino)phenylmethylene)-2-oxo-, methyl ester, (3Z)-; methyl (3Z)-3-[({4-[N-methyl-2-(piperazin-1-yl)acetamido]phenyl}amino)(phenyl)methylidene]-2-oxo-2 and 3-dihydro-1H-indole-6-carboxylate; Intedanib Impurity F; Nintedanib Impurity N9; SCHEMBL3157164; SCHEMBL3157176; Nintedanib metabolite BIBF 1053; AT44458; 2243384-62-3; METHYL (E)-3-(((4-(N-METHYL-2-(PIPERAZIN-1-YL)ACETAMIDO)PHENYL)AMINO)(PHENYL)METHYLENE)-2-OXOINDOLINE-6-CARBOXYLATE; CS-0200332
methyl 2-hydroxy-3-[N-[4-[methyl-(2-piperazin-1-ylacetyl)amino]phenyl]-C-phenylcarbonimidoyl]-1H-indole-6-carboxylate
InChI=1S/C30H31N5O4/c1-34(26(36)19-35-16-14-31-15-17-35)23-11-9-22(10-12-23)32-28(20-6-4-3-5-7-20)27-24-13-8-21(30(38)39-2)18-25(24)33-29(27)37/h3-13,18,31,33,37H,14-17,19H2,1-2H3